LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
|Articles|January 3, 2019
- Dermatology Times, January 2019 (Vol. 40, No. 1)
- Volume 40
- Issue 1
AAD annual meeting starts March 1
Author(s)Dermatology Times Staff
The American Academy of Dermatology annual meeting will be held from March 1-5 in Washington, D.C.
Advertisement
Early bird registration for the American Academy of Dermatology annual meeting closes January 23. Advance registration will run through February 20 for the meeting which runs March 1-5 in Washington, D.C.
For more information about the meeting, visit:
Articles in this issue
over 7 years ago
Medicare physician fee schedule changesover 7 years ago
Access to dermatologic care varies by demographicover 7 years ago
Digital tools impact daily dermatology practiceover 7 years ago
AAD updates cutaneous melanoma guidelinesover 7 years ago
Artificial Intelligence. Friend or foe of dermatology?over 7 years ago
Warning signs of life-threatening purpuraover 7 years ago
Optimize clinical trial recruitment with digital platformsover 7 years ago
Digital health and dermatologyover 7 years ago
The future of dermatologyAdvertisement
Related to this article
Sol-Gel Technologies has completed patient follow-up in its pivotal phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected in late November 2026.
Two small clinical studies evaluated skincare and dermabrasion for changes in skin quality among individuals taking medical weight loss medications.
Two-year POETYK PsA-2 data showed sustained ACR and minimal disease activity responses with deucravacitinib and no new safety signals.
Faculty from the Cutaneous Oncology Workshop answer practical questions spanning skin cancer prevention, diagnosis, treatment, and follow-up.
Two new Neutrogena facial sunscreens incorporate bemotrizinol, the first new sunscreen active ingredient added to the US OTC monograph in decades.
Longer treatment duration was independently associated with VASI improvement, while publicly insured patients experienced higher topical JAK inhibitor denial rates.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
Advertisement
Advertisement
Trending on Dermatology Times
1
Neutrogena Launches New Sunscreens With Newly Permitted UV Filter Bemotrizinol
2
Two-Year POETYK PsA-2 Data Show Durable Deucravacitinib Responses in Psoriatic Arthritis
3
Longer Topical JAK Inhibitor Treatment Linked to Vitiligo Improvement in Real-World Study
4
Sun Protection in Beauty Routines: Is SPF Makeup Enough?
5